Rationale for a study adding tamoxifen to HRT.
Rotmensz
N
N
European Institute of Oncology, Milan, Italy. nicole.rotmensz@ieo.it
Decensi
A
A
Maisonneuve
P
P
Costa
A
A
Sacchini
V
V
Travaglini
R
R
D'Aiuto
G
G
Lovison
F
F
Gucciardo
G
G
Muraca
M G
MG
Pizzichetta
M A
MA
Conforti
S
S
Robertson
C
C
Boyle
P
P
Veronesi
U
U
D000328:Adult; D000368:Aged; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage*; D001943:Breast Neoplasms / Q000517:prevention & control*; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D020249:Hormone Replacement Therapy / Q000379:methods*; D006801:Humans; D008875:Middle Aged; D016032:Randomized Controlled Trials as Topic; D020845:Selective Estrogen Receptor Modulators / Q000008:administration & dosage*; D013629:Tamoxifen / Q000008:administration & dosage*
D018931:Antineoplastic Agents, Hormonal; D020845:Selective Estrogen Receptor Modulators; D013629:Tamoxifen